Table 1 Performance comparison of Veri-Q opti COVID-19 IgG and IgM ELISA (MiCo BioMed, Gyeonggi-do, Republic of Korea) with the two conventional ELISAs.

From: Performance evaluation of microfluidic microplate-based fluorescent ELISA for qualitative detection of SARS-CoV-2–specific IgG and IgM

Veri-Q Opti COVID-19 ELISA

Positive

Negative

PPA% (95% CI)

NPA% (95% CI)

TPA% (95% CI)

Kappa (95% CI)

IgG

SCoV-2 Detect IgG ELISAa

 Positive

66

4

97.1 (89.3–99.8)

98.0 (94.8–99.4)

97.8 (95.1–99.1)

0.94 (0.90–0.99)

 Negative

2

198

 

Veri-Q COVID-19 IgG ELISAb

 Positive

60

10

100 (92.8–100.0)

95.2 (91.4–97.5)

96.3 (93.2–98.1)

0.90 (0.84–0.96)

 Negative

0

200

IgM

SCoV-2 Detect IgM ELISAa

 Positive

59

7

93.7 (84.3–98.0)

96.6 (93.1–98.5)

95.9 (92.8–97.8)

0.89 (0.82–0.95)

 Negative

4

200

 

Veri-Q COVID-19 IgM ELISAb

 Positive

29

37

100 (86.1–100.0)

84.6 (79.5–88.7)

86.3 (81.7–89.9)

0.54 (0.42–0.66)

 Negative

0

204

  1. ELISA enzyme-linked immunosorbent assay, PPA positive percent agreement, NPA negative percent agreement, TPA total percent agreement, CI confidence interval.
  2. aInBios, Seattle, WA.
  3. bMiCo BioMed, Gyeonggi-do, Republic of Korea.